ACADIA Pharmaceuticals Inc. ACAD
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.20B | 1.14B | 1.10B | 1.07B | 1.05B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.20B | 1.14B | 1.10B | 1.07B | 1.05B |
| Cost of Revenue | 433.88M | 431.99M | 420.80M | 417.80M | 429.35M |
| Gross Profit | 768.42M | 706.66M | 674.45M | 653.71M | 617.77M |
| SG&A Expenses | 646.09M | 620.29M | 593.54M | 548.89M | 523.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.08B | 1.05B | 1.01B | 966.69M | 952.71M |
| Operating Income | 122.33M | 86.37M | 80.91M | 104.81M | 94.41M |
| Income Before Tax | 157.21M | 121.37M | 115.11M | 138.90M | 273.67M |
| Income Tax Expenses | -205.02M | -259.12M | -260.54M | -252.10M | 12.50M |
| Earnings from Continuing Operations | 362.23 | 380.48 | 375.65 | 391.00 | 261.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 362.23M | 380.48M | 375.65M | 391.00M | 261.17M |
| EBIT | 122.33M | 86.37M | 80.91M | 104.81M | 94.41M |
| EBITDA | 135.06M | 98.39M | 92.71M | 116.57M | 108.46M |
| EPS Basic | 2.13 | 2.25 | 2.22 | 2.31 | 1.56 |
| Normalized Basic EPS | 0.57 | 0.45 | 0.43 | 0.52 | 0.47 |
| EPS Diluted | 2.11 | 2.22 | 2.20 | 2.29 | 1.55 |
| Normalized Diluted EPS | 0.56 | 0.44 | 0.42 | 0.51 | 0.47 |
| Average Basic Shares Outstanding | 684.00M | 680.29M | 676.52M | 672.81M | 670.01M |
| Average Diluted Shares Outstanding | 692.38M | 687.57M | 683.40M | 678.36M | 673.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |